
Helus Pharma shares fall 10.5% on trial safety
Key points
- Helus Pharma (NASDAQ:HELP) reported that experimental psychedelic HLP003 met the primary endpoint in a late-stage depression trial, delivering a 7.6-point placebo-adjusted improvement at six weeks.
- Shares fell 10.5% to $7.94 after the results, leaving the stock down approximately 3% year to date.
- The company reported three treatment-related serious adverse events, including a suicide attempt by a patient who did not respond to treatment.
Helus Pharma (NASDAQ:HELP) reported that its experimental psychedelic drug HLP003 met the primary endpoint in a late-stage depression trial, delivering a 7.6-point placebo-adjusted improvement in symptoms at six weeks.
The clinical result met the study's main efficacy goal, although the announcement also disclosed three serious adverse events considered related to treatment.
One of the reported events involved a suicide attempt by a patient who did not respond to HLP003 treatment.
Barclays described the efficacy result as "very strong" and said it saw "no fundamental reason" for the share decline, while Cantor said a single case did not establish a safety signal in this patient population.
Following the results, the Helus Pharma share price was down 10.5% at $7.94 in U.S. trading, leaving the stock down approximately 3% year to date.
Helus is also developing HLP004 for generalized anxiety disorder, with the company previously targeting the start of a Phase 2 study in the first quarter of 2027.
The company also expects to identify an HLP005 development candidate in the second half of 2027, as it continues advancing its psychedelic drug development pipeline.



